vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and HIVE Digital Technologies Ltd. (HIVE). Click either name above to swap in a different company.

HIVE Digital Technologies Ltd. is the larger business by last-quarter revenue ($93.1M vs $77.6M, roughly 1.2× Bioceres Crop Solutions Corp.). Bioceres Crop Solutions Corp. runs the higher net margin — -9.6% vs -98.1%, a 88.5% gap on every dollar of revenue. On growth, HIVE Digital Technologies Ltd. posted the faster year-over-year revenue change (218.6% vs -16.8%). Over the past eight quarters, HIVE Digital Technologies Ltd.'s revenue compounded faster (102.2% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Mastech Digital, Inc. is a digital transformation and information technology (IT) services company headquartered in Pittsburgh, Pennsylvania, providing services to corporations across North America, Middle East, Asian, and Japan.

BIOX vs HIVE — Head-to-Head

Bigger by revenue
HIVE
HIVE
1.2× larger
HIVE
$93.1M
$77.6M
BIOX
Growing faster (revenue YoY)
HIVE
HIVE
+235.4% gap
HIVE
218.6%
-16.8%
BIOX
Higher net margin
BIOX
BIOX
88.5% more per $
BIOX
-9.6%
-98.1%
HIVE
Faster 2-yr revenue CAGR
HIVE
HIVE
Annualised
HIVE
102.2%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q3 FY2026

Metric
BIOX
BIOX
HIVE
HIVE
Revenue
$77.6M
$93.1M
Net Profit
$-7.4M
$-91.3M
Gross Margin
46.8%
-27.1%
Operating Margin
9.3%
Net Margin
-9.6%
-98.1%
Revenue YoY
-16.8%
218.6%
Net Profit YoY
-20.2%
-234.0%
EPS (diluted)
$-0.12
$-0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
HIVE
HIVE
Q4 25
$93.1M
Q3 25
$77.6M
$87.3M
Q2 25
$45.6M
Q1 25
$60.6M
Q4 24
$98.8M
$29.2M
Q3 24
$93.3M
$22.6M
Q2 24
$32.2M
Q1 24
$84.0M
Net Profit
BIOX
BIOX
HIVE
HIVE
Q4 25
$-91.3M
Q3 25
$-7.4M
$-15.8M
Q2 25
$35.0M
Q1 25
$-1.6M
Q4 24
$605.2K
$68.2M
Q3 24
$-6.2M
$80.0K
Q2 24
$-18.3M
Q1 24
$9.8M
Gross Margin
BIOX
BIOX
HIVE
HIVE
Q4 25
-27.1%
Q3 25
46.8%
4.7%
Q2 25
-13.6%
Q1 25
39.4%
Q4 24
42.0%
-43.7%
Q3 24
40.2%
-66.1%
Q2 24
-7.4%
Q1 24
50.8%
Operating Margin
BIOX
BIOX
HIVE
HIVE
Q4 25
Q3 25
9.3%
Q2 25
Q1 25
1.5%
Q4 24
14.5%
Q3 24
2.5%
Q2 24
Q1 24
15.7%
Net Margin
BIOX
BIOX
HIVE
HIVE
Q4 25
-98.1%
Q3 25
-9.6%
-18.1%
Q2 25
76.8%
Q1 25
-2.6%
Q4 24
0.6%
233.2%
Q3 24
-6.6%
0.4%
Q2 24
-56.7%
Q1 24
11.6%
EPS (diluted)
BIOX
BIOX
HIVE
HIVE
Q4 25
$-0.38
Q3 25
$-0.12
$-0.07
Q2 25
$0.18
Q1 25
$-0.02
Q4 24
$0.00
$0.52
Q3 24
$-0.10
$0.00
Q2 24
$-0.17
Q1 24
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
HIVE
HIVE
Cash + ST InvestmentsLiquidity on hand
$15.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$559.3M
Total Assets
$734.9M
$624.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
HIVE
HIVE
Q4 25
Q3 25
$15.5M
Q2 25
Q1 25
$38.5M
Q4 24
$29.2M
$40.5M
Q3 24
$32.3M
$31.7M
Q2 24
Q1 24
$16.4M
Stockholders' Equity
BIOX
BIOX
HIVE
HIVE
Q4 25
$559.3M
Q3 25
$288.3M
$624.6M
Q2 25
$560.5M
Q1 25
$345.0M
Q4 24
$346.3M
$430.9M
Q3 24
$346.0M
$275.5M
Q2 24
$268.6M
Q1 24
$348.5M
Total Assets
BIOX
BIOX
HIVE
HIVE
Q4 25
$624.0M
Q3 25
$734.9M
$693.0M
Q2 25
$628.7M
Q1 25
$798.2M
Q4 24
$835.2M
$478.6M
Q3 24
$827.3M
$334.7M
Q2 24
Q1 24
$836.1M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
HIVE
HIVE
Operating Cash FlowLast quarter
$14.4M
$46.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
HIVE
HIVE
Q4 25
$46.0M
Q3 25
$14.4M
$-10.6M
Q2 25
$10.2M
Q1 25
$23.3M
Q4 24
$-5.4M
$-28.5M
Q3 24
$5.2M
$-2.2M
Q2 24
$-4.4M
Q1 24
$-17.4M
Free Cash Flow
BIOX
BIOX
HIVE
HIVE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$-55.5M
Q3 24
$-34.7M
Q2 24
Q1 24
FCF Margin
BIOX
BIOX
HIVE
HIVE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-189.9%
Q3 24
-153.4%
Q2 24
Q1 24
Capex Intensity
BIOX
BIOX
HIVE
HIVE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
92.5%
Q3 24
143.9%
Q2 24
Q1 24
Cash Conversion
BIOX
BIOX
HIVE
HIVE
Q4 25
Q3 25
Q2 25
0.29×
Q1 25
Q4 24
-8.85×
-0.42×
Q3 24
-26.94×
Q2 24
Q1 24
-1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons